Mechanism of Action
The Wolverine stack targets tissue repair through two complementary peptide mechanisms that operate via different but synergistic pathways.
BPC-157 Component
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid pentadecapeptide derived from a gastric juice protein. In the context of the Wolverine stack, it provides localized repair signaling: promoting angiogenesis (new blood vessel formation at injury sites), upregulating growth hormone receptor expression in tendon fibroblasts, and activating the nitric oxide-cGMP pathway to reduce inflammation and accelerate healing. It is orally bioavailable and stable in gastric acid, allowing both injectable and enteric protocols.TB-500 Component
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino acid peptide naturally concentrated in platelets and wound fluid. It drives systemic tissue repair by promoting G-actin sequestration, cell migration, and anti-inflammatory signaling. The LKKTETQ active fragment enables cells to reorganize cytoskeletal actin, facilitating wound closure and tissue remodeling. Its extended half-life of approximately 5 days allows systemic distribution with twice-weekly dosing.Synergistic Action
The two peptides target different but complementary steps in the healing cascade: BPC-157 initiates local vascular growth and fibroblast activation, while TB-500 amplifies cell migration and systemic anti-inflammatory responses. Research in rodent tendon injury models shows additive healing outcomes when both pathways are simultaneously engaged.Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General healing / recovery | 500 µg | 3x per week | Subcutaneous |
| Acute injury (loading) | 750-1,000 µg | 3x per week x 2 weeks | Subcutaneous |
| Maintenance / prevention | 250-500 µg | 2x per week | Subcutaneous |
| Oral (gut focus) | 500 µg BPC-157 only | Once daily | Oral capsule (BPC-157 component) |
Inject at or near injury site when possible. Reconstitute 10 mg (5+5) vial with 2 mL BAC water for 5 mg/mL total concentration; 500 µg = 0.1 mL draw.
Calculate your Wolverine dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Overview
BPC-157 Individual EvidenceCLINICAL
PreclinicalOver 200 published animal studies demonstrate BPC-157 efficacy in tendon repair, gut healing, bone repair, and neural protection. No completed human clinical trials as of 2026. Mechanism is well-characterized in rodent models across multiple injury types.
TB-500 Individual EvidenceCLINICAL
PreclinicalTB-500 (Thymosin Beta-4 fragment) has published preclinical evidence in cardiac repair (post-MI), tendon healing, and corneal regeneration. Parent compound Thymosin Beta-4 completed Phase I cardiac trials (RegeneRx). No human data specifically for the TB-500 fragment.
Combination Stack ReportsCOMMUNITY
CommunityThe Wolverine combination is widely reported in bodybuilding and biohacking communities for tendon and muscle injury recovery. Anecdotal reports consistently describe faster return to training after acute injury. No peer-reviewed combination studies exist; individual component research supports the rationale.
Reconstitution Guide
Standard Reconstitution (10 mg vial)
A Wolverine vial contains BPC-157 5 mg + TB-500 5 mg = 10 mg total. Add 2 mL bacteriostatic water for a total concentration of 5 mg/mL (2.5 mg/mL each component).Draw Volume Calculator
With 2 mL BAC water in a 10 mg vial: 250 µg dose = 0.05 mL (5 units on an insulin syringe) 500 µg dose = 0.10 mL (10 units), standard starting dose 750 µg dose = 0.15 mL (15 units) 1,000 µg dose = 0.20 mL (20 units)Storage After Reconstitution
Store at 2-8°C. Use within 28-30 days. Do not freeze reconstituted vials. Keep away from light. Peptide stability is maintained at refrigerator temperature for this window.Safety Profile
The individual safety data for BPC-157 and TB-500 is well-characterized in preclinical research. No significant adverse effects have been reported in animal studies at research doses. Common reports in community use include mild injection site discomfort and transient redness.
BPC-157 Safety
No LD50 established in animal studies; considered extremely low toxicity. Stable and non-immunogenic. No carcinogenicity, mutagenicity, or teratogenicity signals in preclinical data. No human safety data from controlled trials.TB-500 Safety
Well-tolerated in Phase I cardiac trials (parent Thymosin Beta-4). Transient injection site reactions possible. WADA prohibited under S2 (Peptide Hormones / Growth Factors) due to the TB-500 / Thymosin Beta-4 classification.Combination Safety
No interaction data exists for the combination. Based on distinct mechanisms and routes of action, no pharmacological antagonism or additive toxicity is expected at research doses.References
- [1]Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016. PMID:26517938
- [2]Goldstein AL, et al. "Thymosin beta4: a multi-functional regenerative peptide." Nat Rev Drug Discov. 2012. PMID:22265691
- [3]Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des. 2011. PMID:21348480